Kallyope Inc. — Biomedical Watch V2

Traitements9programmes

Essais4liés

Publications4liées

SourceDBlocale

Traitements

9

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
ElismetrepThis is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.	Migraine	Phase 3	À vérifier	United States	À vérifier
Elismetrep (K-304) 10 mgThis is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.	Migraine	Phase 2	À vérifier	United States	À vérifier
Elismetrep (K-304) 2 mgThis is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.	Migraine	Phase 2	À vérifier	United States	À vérifier
Elismetrep (K-304) 20 mgThis is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.	Migraine	Phase 2	À vérifier	United States	À vérifier
Elismetrep (K-304) 5 mgThis is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.	Migraine	Phase 2	À vérifier	United States	À vérifier
ElismetrepThis is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.	Migraine	Phase 3	À vérifier	United States	À vérifier
ElismetrepThis is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.	Migraine	Phase 3	À vérifier	United States	À vérifier
Elismetrep (K-304) 2 mgThis is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.	Migraine	Phase 2	À vérifier	United States	À vérifier
ElismetrepThis is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.	Migraine	Phase 3	À vérifier	United States	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
Elismetrep	Migraine	Phase 3	NCT07816367	A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine	NOT_YET_RECRUITING
Elismetrep (K-304) 2 mg	Migraine	Phase 2	NCT06848075	A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine	COMPLETED
Elismetrep	Migraine	Phase 3	NCT07645924	A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine	RECRUITING
Elismetrep	Migraine	Phase 3	NCT07674654	A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine	RECRUITING

Publications

4

Molécule	Indication / population	Titre	Journal	Date
Elismetrep (K-304) 5 mg		Interaction of magnolol with bovine serum albumin: a fluorescence-quenching study.	Analytical and bioanalytical chemistry
Elismetrep (K-304) 10 mg		Associative charge transfer reactions. Temperature effects and mechanism of the gas-phase polymerization of propene initiated by a benzene radical cation.	The journal of physical chemistry. A
Elismetrep (K-304) 10 mg		Thermodynamics, conformation and active sites of the binding of Zn-Nd hetero-bimetallic Schiff base to bovine serum albumin.	Journal of fluorescence
Elismetrep (K-304) 10 mg		Binding of dihydromyricetin to human hemoglobin: fluorescence and circular dichroism studies.	Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy